{"links":{"html":"https://www.erudio.com/reports/krascendo-1-nct06497556","json":"https://www.erudio.com/reports/krascendo-1-nct06497556.json","markdown":"https://www.erudio.com/reports/krascendo-1-nct06497556.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"krascendo-1-06497556"}},"request":"https://www.erudio.com/contact?report=krascendo-1-06497556"},"offer":{"cited_commentary_sources":16,"verified_hcp_statements":27,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":750,"identity_verified_people":13,"optional":true,"price_per_verified_person_usd":15,"price_usd":195,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"krascendo-1-nct06497556"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=krascendo-1-06497556","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/krascendo-1-nct06497556","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified HCP statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-18T06:05:41.830153Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":1},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":7,"title":"Primary endpoint: Progression-Free Survival (PFS)"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":12,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":10,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":9,"title":"Perceived advance and possible practice impact"},{"claim_count":11,"coverage":"discussed","id":"A2","source_count":8,"title":"Topline uncertainty and presentation expectations"},{"claim_count":1,"coverage":"discussed","id":"A3","source_count":1,"title":"Heterogeneity and possible combination strategies"}],"counts":{"cited_sources":17,"claims_by_expression_type":{"comparison":3,"interpretation":1,"opinion":3,"primary_context":3,"question":1,"restatement":9,"uncertainty":2,"unspecified":5},"claims_by_kind":{"attributed_opinion":10,"protocol_statement":1,"source_observation":16},"evidence_units":32,"findings":4,"people_cited":15,"people_identity_verified":13,"people_total":18,"screened_sources":26,"verified_claims":27},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":10,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":11,"passages":12,"sources":12,"sources_by_kind":{"commentary":12}},"title":"Favorable topline reactions do not yet constitute a full benefit–risk assessment"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":4,"views":1},"has_counterview":false,"limitations":3,"links":{"context":1,"support":13},"ma_question":true,"named_voices":3,"passages":4,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"The perceived advance is anchored in limitations of current options and the value of direct comparison"},{"id":"F3","structure":{"claims":1,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":0},"has_counterview":false,"limitations":2,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Heterogeneity sustains interest in combinations beyond the single-agent comparison"},{"id":"F4","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":1},"has_counterview":false,"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":3,"passages":3,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Potential practice impact remains an explicit question pending fuller data"}],"medical_affairs_question":"What efficacy, survival-maturity and tolerability details are needed before the announcement can support a complete benefit–risk discussion?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Favorable topline reactions, with important limits on what they establish"},{"id":"section-2","level":2,"title":"Why a direct comparative advance mattered to these speakers"},{"id":"section-3","level":2,"title":"Heterogeneity keeps combinations in the discussion"},{"id":"section-4","level":2,"title":"Practice impact was anticipated, not declared"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS)"},{"findings":[{"id":"F1","shared_claims":5}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":4}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":3}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-18T06:05:41.830153Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-18T06:17:16Z","record_hash":"5e3bf3e212887740aa5762ac59ac5564687e1715f46182de10b505937b484c61","release_hash":"2af386ac68ea7ed0efc2c6a281e086892c6f2bb7123627e3b7921fe04daa3abb","report_id":"erudio-nct06497556","run_id":"ea954ce6-f8aa-4a9c-9f20-096433718fa9","schema_version":"5.0","slug":"krascendo-1-06497556","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"KRAScendo-1 asks whether divarasib can improve outcomes over sotorasib or adagrasib for people with advanced or metastatic non-small cell lung cancer bearing KRAS G12C mutations after earlier systemic treatment. Discussion covers direct comparisons between targeted agents, progression-free and overall survival, information needed to assess benefits and risks, and potential implications for treatment choices. The sources reviewed for this edition reflect commentary before the main results presentation anticipated at ESMO 2026.","meta_description":"26 sources screened · 27 verified HCP statements from 17 sources · 4 findings. Updated Oct 18, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-53e1946668fd5f353bab","claim-56a64e0711204537eb24"],"id":"F2","paraphrase":"In a YouTube video, a speaker described the question of whether divarasib could improve outcomes relative to sotorasib or adagrasib for recurrent, advanced NSCLC with a KRAS G12C mutation.","publication_caveats":["This discussion concerns the study's design and comparative purpose, not KRAScendo-1 results.","The speaker refers first to Phase I and then to Phase II supporting evidence without clarifying the change."],"source_channel":"youtube","source_date":{"reason":"A publication date for the video is not available in the sources reviewed for this edition.","status":"unavailable"},"title":"The perceived advance is anchored in limitations of current options and the value of direct comparison"},{"cited_claim_ids":["claim-d4c339a4301751da538c"],"id":"F4","paraphrase":"An X post listing KRAScendo-1 among several studies asked which results might change clinical practice.","publication_caveats":["The question concerned multiple studies, not KRAScendo-1 alone.","The author's clinical role is not stated in the sources reviewed for this edition.","The exchange was not evaluated in full, so additional views may be missing."],"source_channel":"x_thread","source_date":"2026-10-11","title":"Potential practice impact remains an explicit question pending fuller data"}]},"publication":{"approved_at":"2026-10-18T06:17:16Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":26},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","Most efficacy reactions describe company-announced topline findings rather than independent assessment of a full trial dataset; numerical treatment effects and substantive comparative safety commentary are unavailable here.","No full protocol, exact-trial results publication or divarasib prescribing label was available among the sources reviewed. This does not establish that such materials do not exist.","Discussion using unnamed references or different transcription forms may be missing, so the report is not an exhaustive account of public or clinical opinion.","One included social-media discussion was not fully evaluated beyond the statements described in this report; additional views from it may be missing.","Repeated posts and shared company headlines do not represent independent clinical assessments.","The video account has no available publication date, preventing reliable chronological comparison with the dated posts.","Chandrakanth's clinical role is not established in the sources reviewed for this edition."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":15,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":16,"methods":1},"count":17,"evidence_window":{"end":"2026-10-11","start":"2026-06-18"},"retrieval_snapshot":"2026-10-18T04:12:12.225737Z","timeline":[{"count":1,"week":"2026-W25"},{"count":9,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":3,"week":"2026-W39"},{"count":1,"week":"2026-W41"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT06497556:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06497556:context","quote_policy":"short_quote_link_out"},{"id":"openfda:c80a362c-7ac3-4894-a076-0691e68ef8c1:20250122","quote_policy":"short_quote_link_out"},{"id":"openfda:0b8bf078-34c2-4f45-9012-38a8ac082b01:20260325","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806072268122136613:165c83a4-5026-4e37-871b-ef01a516b189","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067618342605631648:0e3ba86b-82e6-4c79-b255-c077fef335f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072555908266147888:3b6f26d9-f590-4a9f-b041-bdffb3251f3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072592258688245969:c1e617ef-8343-4386-84ba-2414f28c5f90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072623022842712397:3e1260fa-9c43-451b-8d36-88fb772268b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072623119735377994:bf0e7afa-73d1-4843-a2af-1eb3ad2aa4a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072655307449237535:b73a36b9-e11c-488e-a764-c1b22143aa96","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072678522443772024:16c6cde3-bba8-4543-9a58-f5ce42a9d5de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072716539271188529:e30c1e45-c67b-415f-9d4a-41e6721a89b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072797411051790844:6cb94362-5f79-4f88-9cce-9f0954ea1574","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072962979298254971:eab1f892-e31c-4c59-b882-653e27764354","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074439300653928909:fdf1a0c2-de42-490e-8066-52a4c78c918d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074439975236501957:2b4f6083-e898-4c58-a269-4a27d7e7a24c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074463055732158731:d2fc8f61-e7dd-4ab4-ab14-2f90f8152f93","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074578564788146619:eeebf621-d1d9-48dd-a628-ee5508c034c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102538611212358092:700399e9-ad45-4c4f-8056-e4ebf82271de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102550129924624622:e3475089-f48c-4ce8-b2d8-4f1e97274c72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102657659887571321:e983c9ae-8c3d-4273-8c2f-c1069de0d2bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102673399428653268:9555ed43-917a-41a7-bad9-4996d0949923","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102744801359593968:41fd4fa1-086b-4948-a7d7-f7173f268966","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102775635102007809:022c5c54-563f-4884-9041-89ca62bdef05","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102813261150532034:13a5a12d-9204-4ca9-bf67-2c16c54dc10c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103192918315991505:3ea8ef63-7bf7-4466-81ad-329a29a77443","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107390688413339706:1995d6ed-bfaa-4508-be1b-17f7b6208056","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109345852754206978:c7c8ff61-4c18-439d-bd3f-f1ecc331dbbf","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4_6e-u70jiM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":25,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":26},"count":26,"evidence_window":{"end":"2026-10-11","start":"2024-06-26"},"retrieval_snapshot":"2026-10-18T04:12:12.225737Z","timeline":[{"count":1,"week":"2024-W26"},{"count":1,"week":"2026-W25"},{"count":9,"week":"2026-W27"},{"count":4,"week":"2026-W28"},{"count":8,"week":"2026-W39"},{"count":2,"week":"2026-W41"}],"undated_sources":1}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: divarasib","status":"unmapped"},{"brand_names":["Lumakras"],"label":"sotorasib","slug":"sotorasib"},{"brand_names":["Krazati"],"label":"adagrasib","slug":"adagrasib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"reason":"Unmapped registry condition: KRAS G12C Lung Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"Krascendo 1","aliases":["Krascendo 1","A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer","A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer"],"brief_title":"A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer","collaborators":["Chugai Pharmaceutical"],"conditions":["Non-Small Cell Lung Cancer","KRAS G12C Lung Cancer"],"enrollment":{"count":338,"type":"ACTUAL"},"interventions":[{"name":"Divarasib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Sotorasib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Adagrasib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06497556","official_title":"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-05-19","type":"ACTUAL"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by blinded independent central review (BICR) according to RECIST v1.1, or death from any cause (whichever occurs first)","measure":"Progression-Free Survival (PFS)","timeFrame":"Up to approximately 4 years"}],"registry_last_updated":"2026-09-16","registry_url":"https://clinicaltrials.gov/study/NCT06497556","short_name":"Krascendo 1","short_name_basis":"registry_acronym","sponsor":"Hoffmann-La Roche","start_date":{"date":"2024-09-23","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"BO45217","type":"sponsor_study_id"},{"domain":"EU CT Number","id":"2024-510908-37-00","type":"other"}],"study_type":"INTERVENTIONAL"}}}